Trending Now
Aditxt Inc (NASDAQ:ADTX) surge is linked to its NASDAQ compliance requirement
In after marker trading shares of Aditxt Inc (NASDAQ:ADTX) are trading at $0.54 up another $0.17 (45.27%) from the closing price of...
Bio-Path Holdings (NASDAQ: BPTH) announces the successful completion of the second...
Bio-Path Holdings, Inc. (NASDAQ: BPTH), a pioneer in biotechnology, has recently achieved a critical milestone in its fight against acute myeloid leukemia...
Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc....
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a trailblazer in the development of Antibody Radiation Conjugates (ARCs) and targeted radiotherapy treatments, is at...
Popular News
INOVIO (NASDAQ: INO) Receives Approval to Continue Third Part of Phase...
INOVIO (NASDAQ: INO) has received approval from India's Central Drugs Standard Control Organisation's Drug Controller General of India to continue its phase 3 part...
MAKE IT MODERN
LATEST REVIEWS
Menlo Therapeutics Inc (NASDAQ:MNLO) Reports Positive Data From Phase 2 Clinical...
Menlo Therapeutics Inc (NASDAQ:MNLO) achieved a breakthrough to cure moderate to severe acne vulgaris. It is evident from positive data reported in Phase 2...
MAKE IT MODERN
PERFORMANCE TRAINING
Why Temas Resources Corp could be one of the top mining stocks for 2022
Just a few hours ago, Treasury Sec. Yellen stated, “I expect inflation to remain above 2%, but to diminish over the course...
NantKwest Inc. (NASDAQ:NK) and ImmunityBio Collaborate In Development of Adenovirus COVID-19 Vaccine
NantKwest Inc. (NASDAQ:NK) and ImmunityBio have entered a binding agreement term for co-development, co-manufacturer, and co-commercialization of COVID-19 vaccines and Therapeutics.
NantKwest and ImmunityBio collaborate...
A Snapshot Of Eyepoint Pharmaceuticals Inc’s (NASDAQ:EYPT) Performance In Q3 2020 Ahead Of 3Q...
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) is slated to release its Q3 2020 financial and operational results, but it also recently released its Q3 performance highlights...
Inhibikase Therapeutics Inc. (NASDAQ: IKT) Publishes Study Showing Oral c-Abl Kinase Inhibitor’s Potential Ion...
Inhibikase Therapeutics Inc. (NASDAQ: IKT) has announced a publication detailing the biochemical rationale and possible benefits of Abelson Tyrosine kinase inhibition as a possible...
Ocugen Inc (NASDAQ: OCGN) Announces the Successful Publication of Positive Outcomes of COVID-19 Vaccine...
Ocugen Inc (NASDAQ: OCGN) is pleased to unveil the positive outcomes of a recent Covid-19 Vaccine trial. The study focused on children aged 2-18...
MAKE IT MODERN
POPULAR
